Prevalence and direct costs of patients with neuromyelitis optica: data from Campania region in southern Italy | Zendy

Emanuele Monda | Zendy; Stefano Iucolano | Zendy; Maria Galdo | Zendy; Francesca Futura Bernardi | Zendy; Paolo Chiodini | Zendy; Daniela D’Angela | Zendy; Roberta Giordana | Zendy; Massimo Di Gennaro | Zendy; Ugo Trama | Zendy; Federico Spandonaro | Zendy; Giuseppe Limongelli | Zendy; Barbara Polistena | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prevalence and direct costs of patients with neuromyelitis optica: data from Campania region in southern Italy

Author(s) -

Emanuele Monda,

Stefano Iucolano,

Maria Galdo,

Francesca Futura Bernardi,

Paolo Chiodini,

Daniela D’Angela,

Roberta Giordana,

Massimo Di Gennaro,

Ugo Trama,

Federico Spandonaro,

Giuseppe Limongelli,

Barbara Polistena

Publication year - 2021

Publication title -

future rare diseases

Language(s) - English

Resource type - Journals

ISSN - 2399-5270

DOI - 10.2217/frd-2021-0011

Subject(s) - neuromyelitis optica , medicine , indirect costs , incidence (geometry) , disease burden , euros , burden of disease , public health , pediatrics , disease , population , environmental health , pathology , immunology , multiple sclerosis , business , philosophy , physics , accounting , humanities , optics

Aim: The study aimed to estimate the prevalence and direct costs of neuromyelitis optica (NMO) patients in Campania, Italy. Materials & methods: We retrospectively evaluated 53 NMO patients (mean age: 50.9 ± 16.5 years; 34% men) from the Campania Region administrative databases identified through disease exemption codes in 2018 and analyzed the incidence of NMO among the Campania region population and the disease-related cost. Results: The prevalence of NMO was 0.91 per 100,000 individuals. The average regional cost per NMO patient was 10,836.2 euros. The highest cost was related to drugs (60.6%), followed by hospitalizations (32.7%), diagnostics (4.8%) and laboratory tests (1.0%). Conclusion: NMO is an extremely rare disease with an annual disease-related cost of 0.005% of public health expenditure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research